AVEO Oncology's Fotivda (tivozanib) Receives the US FDA's Approval for the Treatment of R/R Advanced Renal Cell Carcinoma
Shots:
- The approval is based on a P-III TIVO-3 study that involves assessing Fotivda (1.34 mg/qd- with or without food for 21days followed by 7days off treatment) vs sorafenib in 350 patients in a ratio (1:1) with r/r advanced RCC following two or more prior systemic therapies.
- The application is also supported by three additional trials in RCC and includes safety data from 1-000+ trial subjects. The P-III TIVO-3 study results: mPFS (5.6 vs 3.9mos.)- m-OS (16.4 vs 19.2mos.)- ORR (18% vs 8%).
- Fotivda (tivozanib- qd- PO) is a VEGF tyrosine kinase inhibitor and is available to patients in the US by Mar 31- 2021
Ref: Business Wire | Image: AVEO Oncology
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com